Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 13/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7572606 | 0.84 | P2RX7 (0.60) | P2RX7MEN1ALDH1A1KMT2A | |
| SCHEMBL7572059 | 0.82 | P2RX7 (0.60) | P2RX7MEN1ALDH1A1KMT2A | |
| SCHEMBL7576813 | 0.80 | MEN1 (0.48) | P2RX7MEN1ALDH1A1KMT2A | |
| SCHEMBL7572585 | 0.76 | P2RX7 (0.70) | P2RX7MEN1ALDH1A1KMT2A | |
| SCHEMBL7568709 | 0.74 | P2RX7 (1.00) | P2RX7MEN1ALDH1A1KMT2A | |
| SCHEMBL5422048 | 0.74 | P2RX7 (0.56) | P2RX7MEN1ALDH1A1KMT2A | |
| SCHEMBL4878448 | 0.74 | P2RX7 (0.66) | P2RX7 | |
| SCHEMBL5431054 | 0.73 | P2RX7 (0.60) | P2RX7MEN1ALDH1A1KMT2AHDAC11 | |
| SCHEMBL4877058 | 0.73 | P2RX7 (0.64) | P2RX7 | |
| SCHEMBL3458610 | 0.72 | P2RX7 (0.68) | P2RX7MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1036059-B1 | ADAMANTANE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2002-09-18 | — | — | EP | claimed |
| US-6303659-B2 | Compounds | ASTRAZENECA AB (SE) | 2001-10-16 | — | — | US | claimed |
| US-6201024-B1 | EFFECTIVE P2X7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISORDERS | ASTRAZENECA UK LIMITED (GB) | 2001-03-13 | — | — | US | claimed |
| EP-1036059-B1 | ADAMANTANE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2002-09-18 | — | — | EP | disclosed |
| US-6303659-B2 | Compounds | ASTRAZENECA AB (SE) | 2001-10-16 | — | — | US | disclosed |
| US-6258838-B1 | Compounds | ASTRAZENECA AB (SE) | 2001-07-10 | — | — | US | disclosed |
| US-20010003121-A1 | Novel compounds | ASTRAZENECA UK LIMITED | 2001-06-07 | — | — | US | disclosed |
| US-6201024-B1 | EFFECTIVE P2X7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISORDERS | ASTRAZENECA UK LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| EP-1036059-A1 | ADAMANTANE DERIVATIVES | AstraZeneca UK Limited (GB) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999029661-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010003121-A1 | Novel compounds | APP, BACE1, CHRNA5 | P2RX7 311/4885MEN1 1930/4885ALDH1A1 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.